BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36123895)

  • 1. SLC22A8: An indicator for tumor immune microenvironment and prognosis of ccRCC from a comprehensive analysis of bioinformatics.
    Xu K; Wu Y; Chi H; Li Y; She Y; Yin X; Liu X; He B; Li X; Du H
    Medicine (Baltimore); 2022 Sep; 101(37):e30270. PubMed ID: 36123895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.
    Cui Y; Zhou Z; Chai Y; Zhang Y
    J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive bioinformatics analysis of KIF20A as a prognosis biomarker for clear cell renal cell carcinoma.
    Xie C; Yiu W; Mo Y
    Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):116-124. PubMed ID: 38650144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
    Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
    Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.
    Xu Z; Wu Y; Fu G; Chen X; Sun J; Tian J; Jiang P; Wang Y; Jin B
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma.
    Zhang ZC; Liu YF; Xi P; Nie YC; Sun T; Gong BB
    Hereditas; 2023 Jan; 160(1):1. PubMed ID: 36635779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential biomarkers for progression and prognosis of renal clear cell carcinoma by comprehensive bioinformatics analysis.
    Dong H; He Z; Wang H; Ding M; Huang Y; Li H; Shi H; Mao L; Hu C; Wang J
    Technol Health Care; 2024; 32(2):897-914. PubMed ID: 37483037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of
    Wang T; Xie F; Li YH; Liang B
    Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.
    Meng W; Chen B; Jiang Z; Cai B; Ma L; Guan Y
    Transl Cancer Res; 2023 Aug; 12(8):2071-2098. PubMed ID: 37701098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT‑qPCR, Western blotting, and immunohistochemistry.
    Han D; Yu Z; Zhang H; Liu H; Wang B; Qian D
    Bioengineered; 2021 Dec; 12(2):10891-10904. PubMed ID: 34845968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
    Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
    Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wiskott-Aldrich syndrome gene as a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.
    Ding G; Wang T; Liu S; Zhou Z; Ma J; Wu J
    Front Immunol; 2023; 14():1102824. PubMed ID: 37122750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin dependent kinase inhibitor 3 (CDKN3) upregulation is associated with unfavorable prognosis in clear cell renal cell carcinoma and shapes tumor immune microenvironment: A bioinformatics analysis.
    Al Sharie AH; Abu Zahra AM; El-Elimat T; Darweesh RF; Al-Khaldi AK; Abu Mousa BM; Amer MSB; Al Zu'bi YO; Al-Kammash K; Abu Lil A; Al Malkawi AA; Alazzeh Z; Alali FQ
    Medicine (Baltimore); 2023 Sep; 102(36):e35004. PubMed ID: 37682177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive insights on pivotal prognostic signature involved in clear cell renal cell carcinoma microenvironment using the ESTIMATE algorithm.
    Luo J; Xie Y; Zheng Y; Wang C; Qi F; Hu J; Xu Y
    Cancer Med; 2020 Jun; 9(12):4310-4323. PubMed ID: 32311223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.